Holen Sie sich die Stockscreener-App
0.6087
22.02%
0.1087
Handel nachbörslich:
.59
-0.0187
-3.07%
Glucotrack Inc Aktie (GCTK) Neueste Nachrichten
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions - marketscreener.com
Implantable glucose sensor designed for multi-year use without wearables - Stock Titan
GCTK Stock Price, Quote & Chart | GLUCOTRACK INC (NASDAQ:GCTK) - ChartMill
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Sahm
GlucoTrack Faces Multiple Nasdaq Deficiency Notices, Delisting Risk - TipRanks
Glucotrack receives Nasdaq delisting notice over listing rule deficiencies By Investing.com - Investing.com South Africa
Glucotrack receives Nasdaq delisting notice over listing rule deficiencies - Investing.com
Glucotrack Received Notice of Delisting - TradingView
Glucotrack (GCTK) cited for bid price and equity Nasdaq deficiencies - Stock Titan
Armistice Capital (GCTK) reports 102,115 shares, 4.99% ownership - Stock Titan
Glucotrack Reports Q1 2026 Results and Advances IDE Submission for Implantable Glucose Monitor - Minichart
Glucotrack's 3-Year CGM Aims to Revolutionize Diabetes Management - BriefGlance
TradingKey - TradingKey
Glucotrack 1Q Loss/Shr $2.65 >GCTK - Moomoo
Glucotrack Reports Q1 2026 Net Loss of $4.3M, Cash $3.9M, Files IDE for Implantable CBGM - TradingView
Glucotrack, Inc. Q1 2026: Net loss $(4.33M), EPS $(2.65) — 10-Q Summary - TradingView
Glucotrack, Inc. Submits IDE Application to FDA for Implantable Continuous Blood Glucose Monitoring System and Reports Q1 2026 Financial Results - Quiver Quantitative
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
GlucoTrack, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Glucotrack (GCTK) posts Q1 loss as cash tightens and Nasdaq flags delisting - Stock Titan
Glucotrack (NASDAQ: GCTK) Q1 2026 results, IDE filing and cash runway - Stock Titan
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewswire Inc.
GlucoTrack Stock Short Interest Rises to 59.4% - Moomoo
What you need to know before buying GlucoTrack (GCTK) (+0.76%) 2026-05-08Mid Cap Momentum - newser.com
How GlucoTrack (GCTK) maintains its asset base | GCTK: GlucoTrack Q Results Lack Revenue, EPS DataFinancial Summary - newser.com
GlucoTrack Files IDE for Implantable Glucose Monitor - TipRanks
IDE filing advances Glucotrack (NASDAQ: GCTK) implantable glucose monitor - Stock Titan
Glucotrack Submits Blood Glucose Monitoring Technology to FDA - Yahoo Finance
Glucotrack Submits IDE Application for U.S. Clinical Study of Its Implantable Continuous Blood Glucose Monitoring System - citybiz
Glucotrack Submits IDE to FDA for Implantable Continuous Blood Glucose Monitoring System - geneonline.com
Glucotrack submits FDA application for implantable glucose monitor - Investing.com
Glucotrack submits FDA application for implantable glucose monitor By Investing.com - Investing.com Canada
GlucoTrack, Inc. announced it has officially submitted an Investigational Device Exemption (IDE) application to US regulators for its innovative implantable continuous glucose monitoring technology. - Bitget
Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology - The Manila Times
Glucotrack, Inc. Submits Investigational Device Exemption Application to FDA for Continuous Blood Glucose Monitoring Technology - Quiver Quantitative
Implantable diabetes monitor moves toward U.S. trial without a wearable - Stock Titan
Glucotrack Announces IDE Submission for U.S. Clinical Study of Its Novel Implantable Continuous Blood Glucose Monitoring Technology - Moomoo
GCTK Stock Jumps As Implantable CGM Data Impresses - StocksToTrade
GCTK Jumps As GlucoTrack’s Implantable CGM Data Impresses - timothysykes.com
$Glucotrack (GCTK.US)$ no bad。 sell it now - Moomoo
see if this zone is the one. $Glucotrack (GCTK.US)$ - Moomoo
GCTK SEC FilingsGlucotrack 10-K, 10-Q, 8-K Forms - Stock Titan
Needle-free diabetes care: 6 devices that painlessly monitor blood sugar - Labiotech.eu
GlucoTrack Executes Debt-for-Equity Exchange and Investor Update - The Globe and Mail
GlucoTrack Reports Strong Preclinical Data for Implantable CBGM - The Globe and Mail
Peer-Reviewed Study in Journal of Diabetes Research Verifies Glucotrack’s Long‑Term Continuous Blood Glucose Monitoring Technology - citybiz
[EFFECT] Glucotrack, Inc. SEC Filing - Stock Titan
Glucotrack (NASDAQ: GCTK) swaps $988K debt for 1.3M new shares - Stock Titan
Glucotrack publishes 240-day glucose monitor study results By Investing.com - Investing.com South Africa
1.38%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):